Biogen beats expectations, hikes outlook as Alzheimer’s drug Leqembi and other new products gain traction
Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company’s cost cuts showed progress and sales of its breakthrough Alzheimer’s drug, Leqembi, and other new products beat expectations. Biogen now expects full-year adjusted earnings to come […]
Health
